We are monitoring the impact of COVID-19 & Recession alarm on North America Preventive Vaccine Market Get in touch with us for detailed analysis Know More
Share on

North America Preventive Vaccine Market Research Report - By Vaccine Type, End User and Country (The United States, Canada, Mexico and Rest of North America) - Industry Analysis, Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 116
Pages: 145

North America Preventive Vaccine Market Size (2022 to 2027)

The North American Preventive Vaccine Market size was worth USD 16.40 Billion in 2022 and is expected to reach USD 29.63 billion by the end of 2027, growing at a CAGR of 12.56% between 2022 to 2027.

While the preventive vaccine accounts for only 5 % of the global pharmaceuticals market, there has been substantial growth in recent years due to rising incidences of HIV cases and cancer. World Health Organization growth estimations indicate the market may increase at a tremendous rate by introducing new therapeutic, preventive, and adult vaccines.

Vaccination is the process of injecting the vaccine given to stimulate the immune system of an individual. Despite being a small one, the Vaccine market is being exploited by multinational companies due to its growth at a faster rate. There are as many as 120 new vaccines in the pipeline of many major companies and are set to hit the market worldwide in the coming years.

The rise in the frequency of occurrence of infectious diseases, the invention of new vaccines for every other disease, and the increase in the funding for vaccine development help drive the growth of the preventive vaccine market. The rise of investments in the R&D department by the major players, technological advancements, and increasing occurrence of the disease is also helping the growth of the market.

Factors like huge capital investment, strict regulatory policies, and the high cost of treatment hinder the growth of the market.

This research report segmented and sub-segmented the North American Preventive Vaccines Market into the following categories:

By Vaccine Type:

  • Live, Attenuated Vaccines
  • Inactivated Vaccines             
  • Toxoid Vaccines    
  • Subunit Vaccines  
  • Conjugate Vaccines             
  • DNA Vaccines         
  • Recombinant Vector Vaccines          

By End-User:

  • Pediatric Vaccine
    • Pneumococcal
    • MMR
    • Varicella
    • Hepatitis
    • Poliovirus
    • HIB
    • Others
  • Adult Vaccines      
    • Influenza
    • Cervical Cancer
    • Hepatitis
    • Zoster
    • Others

By Country:

  • United States
  • Canada
  • Mexico
  • Rest of North America

Regionally, North America enjoys the major share of the therapeutic vaccine market due to the presence of advanced and active R&D establishments in the region. Multinational vaccine companies have historically conducted much of the innovation, research, and development in vaccine production.

The most promising companies operating in the North American Preventive Vaccine Market profiled in this report are GlaxoSmithKline, PLC, Bavarian Nordic, Merck and Company, CSL Limited, Novartis AG, Emergent BioSolutions Inc., Johnson and Johnson, MedImmune, LLC., Pfizer, Inc. and Sanofi Pasteur.

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                              

                2.2 Analysis Design                                                         

                2.3 Research Phases                                                      

                                2.3.1 Secondary Research                                            

                                2.3.2 Primary Research                                 

                                2.3.3 Econometric Modelling                                     

                                2.3.4 Expert Validation                                  

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

  1. Market Segmentation

                5.1 By Vaccine Type                                                       

                                5.1.1 Live, Attenuated Vaccines                                

                                5.1.2 Inactivted Vaccines                                             

                                5.1.3 Toxoid Vaccines                                    

                                5.1.4 Subunit vaccines                                  

                                5.1.5 Conjugate vaccines                                             

                                5.1.6 DNA vaccines                                         

                                5.1.7 Recombinant vector vaccines                                          

                5.2 By End User                                               

                                5.2.1 Paediatric Vaccine                               

                                                5.2.1.1 Pneumococcal                   

                                                5.2.1.2 MMR                     

                                                5.2.1.3 Varicella               

                                                5.2.1.4 Hepatitis                              

                                                5.2.1.5 Poliovirus                             

                                                5.2.1.6 HIB                         

                                                5.2.1.7 Others                  

                                5.2.2 Adult Vaccines                                      

                                                5.2.2.1 Influenza                             

                                                5.2.2.2 Cervical Cancer                 

                                                5.2.2.3 Hepatitis                              

                                                5.2.2.4 Zoster                   

                                                5.2.2.5 Others                  

  1. Geographical Analysis

                6.1 Introduction                                                              

                6.2 United States                                                            

                6.3 Canada                                                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

  1. Market Leaders' Analysis

                8.1 GlaxoSmithKline, plc.                                                             

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Merck and Company                                                              

                8.3 Bavarian Nordic                                                        

                8.4 CSL Limited                                                 

                8.5 Emergent BioSolutions Inc.                                                  

                8.6 Novartis AG                                                

                8.7 Johnson and Johnson                                                             

                8.8 MedImmune, LLC                                                    

                8.9 Pfizer, Inc.                                                   

                8.10 Sanofi Pasteur                                                        

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

Appendix                                                                           

  1. List of Tables
  2. List of Figures
  1. North America Preventive Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  2. North America Preventive Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Billion)
  3. North America Live, Attenuated Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  4. North America Inactivated Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  5. North America Toxoid Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  6. North America Subunit vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  7. North America Conjugate vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  8. North America DNA vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  9. North America Recombinant vector vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  10. North America Preventive Vaccines Market, By End User, From 2022 - 2027 (USD Billion)
  11. North America Paediatric Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  12. North America Adult Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  13. North America Paediatric Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  14. North America Pneumococcal Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  15. North America MMR Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  16. North America Varicella Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  17. North America Hepatitis Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  18. North America Poliovirus Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  19. North America HIB Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  20. North America Other Paediatric Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  21. North America Adult Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  22. North America Influenza Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  23. North America Cervical Cancer Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  24. North America Hepatitis Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  25. North America Zoster Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  26. North America Other Adult Vaccines Market, By Region, From 2022 - 2027 (USD Billion)
  27. United States Preventive Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Billion)
  28. United States Preventive Vaccines Market, By End User, From 2022 - 2027 (USD Billion)
  29. Canada Preventive Vaccines Market, By Vaccine Type, From 2022 - 2027 (USD Billion)
  30. Canada Preventive Vaccines Market, By End User, From 2022 - 2027 (USD Billion)
  31. United States Paediatric Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  32. Canada Paediatric Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  33. United States Adult Vaccines Market, By Type, From 2022 - 2027 (USD Billion)
  34. Canada Adult Vaccines Market, By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample